Early appropriate diagnostics and treatment of MDR Gram-negative infections

Autores organización
Autores
- Bassetti M
- Kanj SS
- Kiratisin P
- Rodrigues C
- Van Duin D
- Yu Y
Grupos de investigación
Resumen
The term difficult-to-treat resistance has been recently coined to identify Gram-negative bacteria exhibiting resistance to all fluoroquinolones and all ß-lactam categories, including carbapenems. Such bacteria are posing serious challenges to clinicians trying to identify the best therapeutic option for any given patient. Delayed appropriate therapy has been associated with worse outcomes including increase in length of stay, increase in total in-hospital costs and ~20% increase in the risk of in-hospital mortality. In addition, time to appropriate antibiotic therapy has been shown to be an independent predictor of 30 day mortality in patients with resistant organisms. Improving and anticipating aetiological diagnosis through optimizing not only the identification of phenotypic resistance to antibiotic classes/agents, but also the identification of specific resistance mechanisms, would have a major impact on reducing the frequency and duration of inappropriate early antibiotic therapy. In light of these considerations, the present paper reviews the increasing need for rapid diagnosis of bacterial infections and efficient laboratory workflows to confirm diagnoses and facilitate prompt de-escalation to targeted therapy, in line with antimicrobial stewardship principles. Rapid diagnostic tests currently available and future perspectives for their use are discussed. Early appropriate diagnostics and treatment of MDR Gram-negative infections require a multidisciplinary approach that includes multiple different diagnostic methods and further consensus of algorithms, protocols and guidelines to select the optimal antibiotic therapy. © 2022 The Author(s). Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Datos de la publicación
- ISSN/ISSNe:
- 2632-1823, 2632-1823
- Tipo:
- Review
- Páginas:
- -
- Enlace a otro recurso:
- www.scopus.com
Jac-Antimicrobial Resistance Oxford University Press
Citas Recibidas en Web of Science: 14
Citas Recibidas en Scopus: 32
Documentos
- No hay documentos
Filiaciones
Keywords
- adult; algorithm; antibiotic resistance; antibiotic sensitivity; antibiotic therapy; antimicrobial stewardship; bacterial infection; consensus; developing country; diagnostic procedure; early diagnosis; empirical research; Gram negative infection; human; molecularly targeted therapy; mortality; phenotypic variation; practice guideline; Review; workflow
Proyectos asociados
Colonización como factor de riesgo asociado a la infección por Enterobacterales productores de carbapenemasas (CPE) en pacientes hospitalizados en unidades de cuidados intensivos (UCI) en dos instituciones de salud en Colombia
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
PCI-2022-11023 . 2022
Creating a Latin America network for clinical training and support of pharmacists and hospital financial decision makers involved in ASPs
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
UEB-2020-585 . 2020
Caracterización Molecular de Aislamientos Resistentes a Ceftazidime Avibactam en Enterobacterales y Pseudomonas aeruginosa recolectados en cinco Países de América Latina. Molecular mechanisms leading to ceftazidime-avibactam resistance in Enterobacterales and Pseudomonas aeruginosa collected from five Latin American countries
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
UEB-2020-586 . 2020
Haciendo frente a la multidrogo resistencia en Klebsiella pneumoniae: dinámica y evolución de plásmidos portadores de carbapenemasa en un país endémico para KPC
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
2022
Estudio comparativo in vitro de Ceftriaxona-Sulbactam-EDTA y antibióticos comparadores contra bacilos Gram negativos productores de β-lactamasas
Investigador Principal: MARIA VIRGINIA VILLEGAS BOTERO
UEB-ID-2021-638 . 2022
Citar la publicación
Bassetti M,Kanj SS,Kiratisin P,Rodrigues C,Van D,Villegas MV,Yu Y. Early appropriate diagnostics and treatment of MDR Gram-negative infections. JAC Antimicrob Resist. 2022. 4(5):dlac089.